Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June
Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June
CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced management's participation in the Jefferies Global Healthcare Conference and the Goldman Sachs 45th Annual Global Healthcare Conference. With an initial focus in oncology, Foghorn's Gene Traffic Control platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.
马萨诸塞州剑桥，2024年5月28日（GLOBE NEWSWIRE）——Foghorn Therapeutics Inc.（纳斯达克股票代码：FHTX）是一家临床阶段的生物技术公司，开创了一类通过纠正异常基因表达来治疗严重疾病的新药物，今天宣布管理层将参加杰富瑞全球医疗保健会议和高盛45指数第四 年度全球医疗保健会议。Foghorn最初的重点是肿瘤学，其基因流量控制平台以及由此产生的广泛管道有可能改变患有各种疾病的人们的生活。
Jefferies Global Healthcare Conference
杰富瑞全球医疗保健会议
- Presentation: Wednesday, June 5, 2024, at 3:30 p.m. ET at the Marriott Marquis New York, New York
- Foghorn Presenter: Adrian Gottschalk, President and Chief Executive Officer
- Please find a link to the webcast here
- Management will also participate in one-on-one meetings on Wednesday, June 5
- 演讲：美国东部时间 2024 年 6 月 5 日星期三下午 3:30 在纽约马奎斯万豪酒店举行
- Foghorn 主持人：总裁兼首席执行官阿德里安·戈特沙尔克
- 请在此处找到网络直播的链接
- 管理层还将参加6月5日星期三的一对一会议
Goldman Sachs 45th Annual Global Healthcare Conference
高盛 45第四 年度全球医疗保健会议
- Presentation: Monday, June 10, 2024, at 3:20 p.m. ET at the Loews Miami Beach Hotel, Miami Beach, Florida
- Foghorn Presenter: Adrian Gottschalk, President and Chief Executive Officer
- Please find a link to the webcast here
- Management will also participate in one-on-one meetings during the conference
- 演讲：美国东部时间 2024 年 6 月 10 日星期一下午 3:20 在佛罗里达州迈阿密海滩洛伊斯迈阿密海滩酒店举行
- Foghorn 主持人：总裁兼首席执行官阿德里安·戈特沙尔克
- 请在此处找到网络直播的链接
- 管理层还将在会议期间参加一对一的会议
A webcast of both presentations can be accessed under "Events & Presentations" in the Investors section of the Company's website, , and will be available for 30 days.
两场演讲的网络直播均可在公司网站 “投资者” 部分的 “活动与演讲” 下观看，并将持续30天。
About Foghorn Therapeutics
Foghorn Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at for more information about the Company, and follow us on X (formerly Twitter) and LinkedIn.
关于Foghorn Therapeutics
Foghorn Therapeutics正在发现和开发一类针对染色质监管系统中基因决定的依赖关系的新型药物。通过其专有的可扩展基因流量控制平台，Foghorn正在系统地研究、识别和验证染色质监管系统中的潜在药物靶标。该公司正在开发多种肿瘤学候选产品。访问我们的网站，了解有关公司的更多信息，并在 X（前身为 Twitter）和 LinkedIn 上关注我们。
Contacts:
联系人：
Greg Dearborn, Foghorn Therapeutics Inc. (Investors)
gdearborn@foghorntx.com
Greg Dearborn，Foghorn Therapeutics Inc.（投资者）
gdearborn@foghorntx.com
Karin Hellsvik, Foghorn Therapeutics Inc. (Investors & Media)
khellsvik@foghorntx.com
Karin Hellsvik，Foghorn Therapeutics Inc.（投资者与媒体）
khellsvik@foghorntx.com
Adam Silverstein, ScientPR (Media)
adam@scientpr.com
亚当·西尔弗斯坦，ScientPR（媒体）
adam@scientpr.com